| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | FIMM | pan-cancer | AAC | 0.017 | 0.9 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.017 | 0.9 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Roscovitine | GDSC1000 | pan-cancer | AAC | 0.0049 | 0.9 |